Davide Melisi Selected Research

3- (9- fluoro- 2- (piperidin- 1- ylcarbonyl)- 1,2,3,4- tetrahydro(1,4)diazepino(6,7,1- hi)indol- 7- yl)- 4- imidazo(1,2- a)pyridin- 3- yl- 1H- pyrrole- 2,5- dione

1/2020

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Davide Melisi Research Topics

Disease

46	Neoplasms (Cancer) 10/2022 - 04/2003
29	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 04/2008
11	Adenocarcinoma 11/2019 - 03/2015
8	Stomach Neoplasms (Stomach Cancer) 01/2020 - 12/2016
5	Neoplasm Metastasis (Metastasis) 02/2018 - 04/2008
5	Carcinogenesis 02/2018 - 05/2009
4	Cholangiocarcinoma 02/2021 - 01/2020
4	Breast Neoplasms (Breast Cancer) 05/2017 - 04/2003
3	Inflammation (Inflammations) 01/2019 - 02/2018
2	Disease Progression 01/2020 - 10/2019
2	Colorectal Neoplasms (Colorectal Cancer) 08/2017 - 10/2011
2	Male Breast Neoplasms (Male Breast Cancer) 05/2017 - 03/2016
2	Lung Neoplasms (Lung Cancer) 01/2015 - 08/2004
2	Colonic Neoplasms (Colon Cancer) 01/2004 - 04/2003
1	Acinar Cell Carcinoma 01/2022
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/2021
1	Glioma (Gliomas) 12/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Pathologic Neovascularization 01/2020
1	Neoplasms, Cystic, Mucinous, and Serous 01/2019
1	Dysbiosis 10/2018
1	Obesity 10/2018
1	Hemolysis 01/2018
1	Weight Gain 01/2018
1	Malnutrition (Nutritional Deficiencies) 01/2018
1	Thalassemia 01/2018

Drug/Important Bio-Agent (IBA)

15	Gemcitabine FDA Link 12/2021 - 04/2008
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2011
9	Phosphotransferases (Kinase)IBA 01/2021 - 08/2005
8	ErbB Receptors (EGF Receptor)IBA 05/2014 - 04/2003
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2017 - 04/2003
6	Proteins (Proteins, Gene)FDA Link 11/2019 - 08/2005
5	pemigatinibIBA 02/2021 - 01/2020
5	Transcription Factors (Transcription Factor)IBA 11/2020 - 02/2007
4	130-nm albumin-bound paclitaxelIBA 12/2021 - 04/2015
4	LY-2157299IBA 01/2021 - 11/2018
4	Gefitinib (Iressa)FDA Link 12/2005 - 04/2003
4	Tyrosine Kinase InhibitorsIBA 12/2005 - 04/2003
3	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 04/2008
3	Small Interfering RNA (siRNA)IBA 01/2020 - 05/2009
3	Leucovorin (Folinic Acid)FDA Link 01/2020 - 05/2017
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2019
3	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 05/2017
3	Pharmaceutical PreparationsIBA 11/2019 - 02/2007
3	Bevacizumab (Avastin)FDA Link 08/2017 - 09/2011
3	Monoclonal AntibodiesIBA 01/2016 - 08/2004
3	OligonucleotidesIBA 08/2014 - 04/2003
3	LuciferasesIBA 08/2011 - 04/2008
3	vandetanib (ZD6474)IBA 08/2008 - 01/2004
2	Cisplatin (Platino)FDA LinkGeneric 12/2021 - 10/2020
2	durvalumabIBA 01/2021 - 11/2018
2	Angiogenesis InhibitorsIBA 11/2020 - 01/2013
2	Biological ProductsIBA 01/2020 - 07/2017
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 12/2016
2	Interleukin-8 (Interleukin 8)IBA 01/2020 - 08/2017
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 10/2009
2	Hormones (Hormone)IBA 10/2018 - 03/2016
2	Angiopoietin-like ProteinsIBA 02/2018 - 08/2017
2	Mitogen-Activated Protein KinasesIBA 11/2017 - 10/2011
2	LigandsIBA 08/2017 - 01/2016
2	Everolimus FDA Link 05/2017 - 03/2016
2	CytokinesIBA 01/2017 - 05/2009
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 03/2016 - 01/2016
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 03/2016 - 01/2016
2	Toll-Like Receptor 9IBA 08/2014 - 10/2011
2	Cetuximab (Erbitux)FDA Link 10/2011 - 01/2004
2	DNA (Deoxyribonucleic Acid)IBA 10/2009 - 04/2003
2	NF-kappa B (NF-kB)IBA 05/2009 - 02/2007
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 08/2008 - 08/2005
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2006 - 08/2004
2	4- (5- (4- chlorophenyl)- 3- (trifluoromethyl)- 1H- pyrazol- 1- yl)benzenesulfonamideIBA 12/2005 - 04/2003
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2005 - 04/2003
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2005 - 01/2004
1	alectinibIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 12/2021
1	LY3300054IBA 12/2021
1	Antineoplastic Agents (Antineoplastics)IBA 12/2021
1	B7-H1 AntigenIBA 01/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	CollagenIBA 01/2020
1	Fibronectins (Fibronectin)IBA 01/2020
1	3- (9- fluoro- 2- (piperidin- 1- ylcarbonyl)- 1,2,3,4- tetrahydro(1,4)diazepino(6,7,1- hi)indol- 7- yl)- 4- imidazo(1,2- a)pyridin- 3- yl- 1H- pyrrole- 2,5- dioneIBA 01/2020
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2020
1	pyrimidineIBA 11/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 11/2019
1	Decitabine FDA Link 11/2019
1	NucleotidesIBA 11/2019
1	AngiopoietinsIBA 02/2018

Therapy/Procedure

33	Therapeutics 01/2022 - 01/2004
19	Drug Therapy (Chemotherapy) 10/2022 - 08/2005
3	Radiotherapy 01/2013 - 08/2004
2	Nutritional Support (Artificial Feeding) 01/2020 - 01/2018
2	Aftercare (After-Treatment) 08/2018 - 04/2003
2	Neoadjuvant Therapy 08/2018 - 01/2018
2	Oral Administration 08/2011 - 04/2003
1	Intravenous Administration 01/2020
1	Parenteral Nutrition 01/2020
1	Blood Transfusion (Blood Transfusions) 01/2020
1	Adjuvant Chemotherapy 01/2019
1	Immunotherapy 12/2018